Imaging of Oligometastatic Disease

Violi, Naïk Vietti; Hajri, Rami; Haefliger, Laura; Lalonde, Marie Nicod; Villard, Nicolas; Dromain, Clarisse

doi:10.3390/cancers14061427

Cited by 5 publications

(1 citation statement)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The diagnosis of oligometastasis relies on a limited set of criteria: timing (synchronous vs. metachronous), location of metastases (bone vs. visceral), and number of localizations on imaging detection (traditional vs. advanced) [2]. The enhanced detection capability of relatively new imaging methodologies such as PSMA-PET/CT and whole-body MRI may allow for the early detection of small lesions that would have been imperceptible on conventional imaging [11]. Once oligometastasis is diagnosed, treatment options may include surgery, stereotactic body radiotherapy (SBRT), systemic therapy, or a combination of these treatments.…”

Section: Introductionmentioning

confidence: 99%

A Bibliometric Analysis of the Oligometastatic State over the Last Two Decades: A Shifting Paradigm for Oncology? An AIRO Oligometastatic Study Group

Marvaso,

Mastroleo,

Corrao

et al. 2023

Cancers

View full text Add to dashboard Cite

The term “oligometastasis” represents a relatively novel idea, which denotes a condition characterized by cancer dissemination with a limited number of lesions (usually fewer than five). The aim of the present study is to report a bibliometric analysis of the oligometastatic disease/state, incorporating all relevant studies on the topic for more than 20 years. The research strategy included at least one the terms “Oligmetastases”, “Oligometastasis”, “Oligometastatic”, “Oligoprogression, “Oligoprogressive”, “Oligorecurrent”, or “Oligorecurrency” in the title, abstract, and/or keywords. All English-language documents from 1 January 1995 (the year of the earliest available document in Scopus) to 31 December 2022 were considered for the analysis. R code (R version 4.2.0) with R Studio (version 2022.12.0-353) and the Bibliometrix package (version 4.0.1) were used for the analysis. A total of 3304 documents, mainly articles (n = 2083, 63.0%) and reviews (n = 813, 24.6%), were collected from 1995 to 2022. The average annual growth rate of literature on the topic was 26.7%. Overall 15,176 authors published on the topic, with an average of eight authors/publication. From 1995, 69 countries contributed to the literature, with the USA and Italy being the top contributors. Among all keywords used by authors, the top three were oligometastases (19%), SBRT (18%), and radiation therapy (8%). Themes regarding “locoregional treatment”, “organ motion”, and “immunotherapy” were the most recent trend topics, mainly developed from 2019 to 2022, while “high-dose chemotherapy”, “whole-brain radiotherapy”, and “metastatic breast cancer” saw their main development during 2009–2018. Our study shows the exceptionally flourishing scientific production on the oligometastatic state, summarizing the most influential studies and highlighting the future developments and interests. This analysis will serve as a benchmark to identify this area for the attention of researchers worldwide and contribute to the increasing scientific work.

show abstract

Section: Introductionmentioning

confidence: 99%

A Bibliometric Analysis of the Oligometastatic State over the Last Two Decades: A Shifting Paradigm for Oncology? An AIRO Oligometastatic Study Group

Marvaso,

Mastroleo,

Corrao

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

Society 5.0 and Quality Multidisciplinary Care of Malignant Solid Tumors in Low- and Middle-Income Settings

Luvhengo

Kgoebane-Maseko

Phakathi

et al. 2023

Society 5.0 and Next Generation Healthcare

View full text Add to dashboard Cite

Navigating Breast Cancer Oligometastasis and Oligoprogression: Current Landscape and Future Directions

Yoon,

Bazan

2024

Curr Oncol Rep

View full text Add to dashboard Cite

Purpose We examine the potential for curative approaches among metastatic breast cancer (MBC) patients by exploring the recent literature on local ablative therapies like surgery and stereotactic body radiation therapy (SBRT) in patients with oligometastatic (OM) breast cancer. We also cover therapies for MBC patients with oligoprogressive (OP) disease. Key Findings Surgery and SBRT have been studied for OM and OP breast cancer, mainly in retrospective or non-randomized trials. While many studies demonstrated favorable results, a cooperative study and single-institution trial found no support for surgery/SBRT in OM and OP cases, respectively. Conclusion While there is interest in applying local therapies to OM and OP breast cancer, the current randomized data does not back the routine use of surgery or SBRT, particularly when considering the potential for treatment-related toxicities. Future research should refine patient selection through advanced imaging and possibly explore these therapies specifically in patients with hormone receptor-positive or HER2-positive disease.

show abstract

Imaging of Oligometastatic Disease

Cited by 5 publications

References 80 publications

A Bibliometric Analysis of the Oligometastatic State over the Last Two Decades: A Shifting Paradigm for Oncology? An AIRO Oligometastatic Study Group

A Bibliometric Analysis of the Oligometastatic State over the Last Two Decades: A Shifting Paradigm for Oncology? An AIRO Oligometastatic Study Group

Society 5.0 and Quality Multidisciplinary Care of Malignant Solid Tumors in Low- and Middle-Income Settings

Navigating Breast Cancer Oligometastasis and Oligoprogression: Current Landscape and Future Directions

Contact Info

Product

Resources

About